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Depression in patients with multiple sclerosis 
 
Depresija kod oboljelih od multiple skleroze 
 






Objective: The aim of the study was to determine the prevalence of depression in patients with multiple 
sclerosis (MS) and to analyze the link between depression and patient sex, age, clinical course of MS, 
disease duration, antidepressant intake, and degree of disability. 
Patients and methods: The study was conducted on 102 MS patients that had undergone inpatient 
rehabilitation at the Lipik Hospital in the period from May 15, 2015 to September 15, 2015. Data on patient 
age, sex, degree of disability, clinical course of MS, antidepressant use, and time elapsed from MS diagnosis 
were collected. The diagnosis of depressive syndrome was made using the Patient Health Questionnaire-
nine (PHQ-9). Study patients were divided into two groups according to the depressive syndrome absence or 
presence.  
Results: The total number of respondents was 102, of which 31 (30.4%) met the criteria for depressive 
syndrome diagnosis. 10 (32.3%) out of the 31 patients were taking antidepressants.  There was a statistically 
significant positive correlation between the presence of depressive syndrome and higher level of disability 
(P = 0.028), whereas there was no correlation between the presence of depression and sex (P = 0.429), age 
(P = 0.652), disease duration (P = 0.549), and disease course (P = 0.326). 
Conclusion: The high rate of patients screened positive for depression and the fact that only one-third of 
these patients were taking antidepressants call for an active approach to diagnosis and the treatment of 
depression in MS patients. 




Cilj rada: Cilj rada je bio odrediti učestalost depresije  kod oboljelih od multiple skleroze (MS) i 
analizirati povezanost depresije  sa spolom bolesnika, dobi, kliničkim oblikom MS, trajanjem bolesti, 
uzimanjem antidepresiva  i stupnjem onesposobljenosti.  
Ispitanici i metode: Studija je obuhvatila 102 oboljelih od MS koji su u razdoblju od 15. svibnja 2015. do 
15. rujna 2015. provodili stacionarnu rehabilitaciju u Specijalnoj bolnici za medicinsku rehabilitaciju Lipik. 
Prikupljeni su podaci o spolu i dobi ispitanika, stupnju onesposobljenosti, kliničkom obliku MS, uzimanju 
antidepresiva i vremenu proteklom od postavljana dijagnoze MS. Dijagnoza depresivnog sindroma 
postavljena je pomoću upitnika PHQ-9. Ispitanici su podijeljeni u dvije skupine, ovisno o prisutnosti ili 
odsutnosti depresivnog sindroma.  
Rezultati: Ukupan broj ispitanika bio je 102, od kojih je 31 (30,4%) ispunilo kriterije za dijagnozu 
depresivnog sindroma, a 10 njih (32,3%) uzimalo je antidepresive. Nađena je statistički značajna povezanost 
između prisutnosti depresivnog sindroma i višeg stupnja onesposobljenosti (P = 0,028), dok  nije nađena  
između prisutnosti depresivnog sindroma u odnosu na  spol (P = 0,429), životnu dob (P = 0,652), trajanje 
bolesti (P = 0,549)  i klinički tijek  bolesti (P = 0,326).                                                      
Zaključak: Visoka učestalost bolesnika pozitivnih na testu probira na depresiju  i činjenica da samo tre-
ćina njih uzima antidepresive zahtijeva aktivan pristup u dijagnostici i liječenju depresije kod oboljelih od MS. 
Ključne riječi: multipla skleroza, depresija, upitnik PHQ-9. 
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Mood disorders (e.g., depressed mood, anxiety) in 
MS patients have a multifactorial etiology including 
disease-related processes resulting in neural damage, 
genetic and environment-related predispositions, 
normal grieving, and adjustment to loss.
1
 Depression 
can also be a psychological reaction to lifestyle 
changes that occur when patients face the reality of 
living with a chronic disease, as well as the lack of 
social support.
2,3
 If left untreated, depressive 
symptoms in MS patients may worsen over time.
4
 
Depressive symptoms are strongly associated with 
worse self-reported functioning and low health-
related quality of life.
5,6
 MS patients who suffer from  
depression  have a lower coping capacity, higher 
levels of fatigue and reduced adherence to disease-
modifying therapy.
7-9
 Studies evaluating the 
prevalence of depression in MS patients vary in the 
methods used to identify depression. Some use formal 
diagnostic interviews, others diagnoses abstracted 
from administrative databases, and still others 
screening questionnaires or a combination of 
methods. Based on diagnoses conferred by    
interviews or obtained from data sources other than 
questionnaires, the prevalence of depression      
ranges from 3.80% to 68.4%.
10
 When screening 
questionnaires were used to identify depression, the 
prevalence ranged from 6.94% to 70.1%.
10
 The 
estimated prevalence of depression using a mixture of 
methods ranged  from 4.98% to 58.9%, and the 
summary estimate was  23.7% (95% CI: 17.4%-
30.0%).
10
 Only a few previous studies analyzed the 
link between the presence of depression and patient  
age, clinical course of MS, disease duration, and 
degree of disability.
11-13
. The presence of depression 
was found to be significantly associated with older 
age,
11
 but there were no correlations with disease 
duration or disability as measured by EDSS.
12
 The 
SPMS course was found to be the most common 
course of disease in depressed MS patients,
13
 while 
disease duration and the clinical course of MS were 
unrelated to major depressive episodes.
14
 In some 
studies, depression was more common in women,
15,16
 
in others in men,
17
 or the prevalence rate was similar 
in both sexes.
7,18
  Depression is recognized to affect 
the MS population more often than the general 
population.
19
 Patients suffering from other chronic 
neurological diseases also have a high prevalence of 
depression. The prevalence rate in patients with 
Alzheimer's disease is up to 50%, Parkinson's disease 
35%, epilepsy 30%-35%, and myasthenia gravis 
26%.
20-23
  Depression is frequently underdiagnosed 
and undertreated in MS patients, with reported rates 
of missed diagnosis of 23-30%,
24,25
 and inadequate 




In studies using screening questionnaires aiming at 
detecting possible depression, a variety of instruments 
are employed.
27-31
 In our study, we used the Patient 
Health Questionnaire-nine (PHQ-9) as a measuring 
instrument.
29
 In recent years, the PHQ-9 has been 
widely used to measure depression in MS patients,
32-37
 




Due to a wide range in the prevalence of 
depression observed in previous studies and the high 
rates of missed diagnosis, the aim of the study was to 
determine the prevalence of depression in MS 
patients and to analyze the association between 
depression and patient sex, age, clinical course of MS, 
disease duration, degree of disability, and use of 
antidepressants. 
 
Patients and Methods 
 
The study included 102 patients with MS that 
underwent inpatient rehabilitation at Lipik Special 
Hospital for Medical Rehabilitation in the period from 
May 15, 2015 to September 15, 2015. Participating in 
the study were patients older than 18 and diagnosed 
with MS according to the revised McDonald 
criteria.
39
 The exclusion criterion was serious 
cognitive impairment, corticosteroid treatment, or any 
other medical complication in the previous three 
months. Data on patient age, sex, degree of disability, 
clinical course of MS, antidepressant use, and time 
elapsed from MS diagnosis were collected. The 
diagnosis of depressive syndrome was made by use of 
the PHQ-9 questionnaire.
29
 The PHQ-9 is a multiple-
choice self-report inventory screening tool for 
depression. Its nine items pertain to the DSM IV
40
 
criteria for major depressive disorder: (1) Anhedonia, 
(2) Depressed mood, (3) Trouble sleeping, (4) Feeling 
tired, (5) Change in appetite, (6) Guilt, self-blame or 
worthlessness, (7) Trouble concentrating, (8) Feeling 
slowed down or restless, and (9) Thoughts of being 
better off dead or hurting oneself.  Each item is rated 
on a 4-point scale from 0 to 3 (0-Never; 1-Several 
days; 2-More than half the days; and 3-Nearly every 
day). Major depressive syndrome is diagnosed if 5 or 
more of the 9 depressive symptom criteria have been 
present at least “more than half the days” in the past 2 
weeks, and 1 of the symptoms is depressed mood or 
anhedonia. Other depressive syndrome is diagnosed if 
2, 3, or 4 depressive symptoms have been present at 
least “more than half the days” in the past 2 weeks, 
and 1 of the symptoms is depressed mood or 
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anhedonia. One of the 9 symptom criteria (“thoughts 
that you would be better off dead or of hurting 
yourself in some way”) counts if present at all, 
regardless of duration. Additionally, the PHQ-9 has 
established construct validity as a measure of 
depression severity (scores of 5, 10, 15, 20 represent 
cutpoints for mild, moderate, moderately severe and 
severe depression, respectively), making it useful for 
serial monitoring of depressive symptom burden and 
depression treatment outcome
41
. As a screening 
instrument, PHQ-9 provides diagnosis of major 
depressive syndrome and other depressive syndrome. 
The diagnosis of major depressive disorder and other 
depressive disorder requires structured psychiatric 
interviews to confirm the diagnoses of depressive 
syndrome in the screening test. 
Study patients were divided into two groups, 
according to the presence or absence of the depressive 
syndrome. The group with present depressive 
syndrome included those with major as well as other 
depressive syndromes. The degree of disability for all 
study subjects was based on the Expanded Disability 
Status Scale (EDSS),
42
 and assessment of cognitive 
status was performed using the Mini Mental Status 
Exam (MMSE).
43
 The study was approved by the 
Hospital Ethics Committee and patients were required 
to provide written consent for their participation. 
Statistical analysis was performed using the SOFA 
Stats. Comparison of the variables was conducted 





The study included 102 patients, 77 (75.5%) female 
and 25 (24.5%) male, mean age 51.4 years, age range 
25-80 years. The mean time elapsed from MS 
diagnosis was 14.7 years (range, 6 months to 62 years). 
The relapsing-remitting course of the disease (RRMS) 
was experienced by 47 (46.1%), secondary progressive 
MS (SPMS) by 51 (50.0%), primary progressive 
(PPMS) by 3 (2.9%) and benign by 1 (1.0%) patient. 
The mean EDSS was 5.3, range 1.5 to 9. Out of 102 
study patients, 31 (30.4%) screened positive for 
depressive syndrome, with the mean PHQ-9 score of 
14.1 (SD 4.9). Of these 31 patients, 10 (32.3%) were 
taking antidepressants. Out of 31 patients screened 
positive for depressive syndrome, 18 (58.1%) had 
major and 13 (41.9%) other depressive syndrome. 
Patient characteristics according to the presence/ 
absence of depressive syndrome are shown in Table 1. 
In the group of patients with depressive syndrome, 
there was a statistically significantly higher proportion 
of patients with higher level of disability compared 
with the group of patients without depressive 
syndrome (P = 0.028). There were no statistically 
significant between-group differences according to sex 
(P = 0.429), age (P = 0.652), disease duration (P = 
0.549) and disease course (P = 0.326). Due to small 
number of patients that suffered from PPMS and 
benign MS course, only patients with RRMS and 
SPMS were included in the analysis of the relationship 
of depression and MS course. 
 
Table 1 Characteristics of patients screened positive and negative for depressive syndrome 




Screened positive for 
depression 
Pozitivni na depresiju 
Screened negative for 
depression 
Negativni na depresiju 
n (%) 
Age (yrs),   ± SD /Starost 
Female, n (%) / Žensko 
Male, n (%) /Muško 
EDSS,  ± SD 
MS course, n (%)              
     RRMS 
     SPMS                                            
     PPMS                                              
     Bening MS                                                                                                    
Time elapsed from MS diagnosis (yrs),  
 ± SD /vrijeme od dijagnoze MS (god.) 
31 (30.4) 
52.2 ± 9.78 
25 (80.7) 
6  (19.3) 




2  (6.5) 
0  (0.0) 
13.7 ± 8.50 
 
71 (69.6) 
51.0 ± 12.56 
52 (73.2) 
19 (26.8) 




1  (1.4) 
1  (1.4) 
15.1 ± 11.90 
 
EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = 
secondary progressive multiple sclerosis; PPMS = primary progressive multiple sclerosis; Bening MS = benign multiple sclerosis





In our study, the prevalence of depressive 
syndrome in MS patients was 30.4%. The prevalence 
of depression in patients with MS varied significantly 
in published studies. Heterogeneous results in various 
literature reports could be due to differences in the 
methods of data collection, small sample size, study 
design, and differences in the socioeconomic or 
cultural context.
10,12
 The summary estimate of 
depression prevalence in MS patients  is  23.7%,
10
 
which is comparable to our results.  
A limitation of the study was the fact that using 
the PHQ-9 or any other questionnaire does not set a 
definitive diagnosis of depression, but provides 
screening instead. Therefore, positive patients require 
further psychiatric assessment.  
The proportion of patients screened positive               
for depression who reported ongoing use of 
antidepressants was  low (32.3%). Such findings           




We found no significant between-group sex 





 there were no differences in the 
prevalence of depression between men and women 
either, whereas Hakim et al.
17
 reported a higher 
prevalence in men. In two studies by Patten et al., 
depression was more common in women.
15,16
 As other 
factors that may influence sex difference in the 
prevalence of depression were not analyzed in these 
studies, the reasons for different findings remain 
unknown. 
In our study, patients with depressive syndrome 
had a higher level of disability as measured by EDSS 
score compared with patients without depression, 
whereas we found no association of the presence of 
depressive syndrome with age, disease duration and 
disease course. Positive correlation between 
depression and higher disability level was also 
observed in the studies that analyzed depression 
prevalence in various chronic medical conditions, and 
could be the result of numerous effects of physical 
disability on various aspects of patient life, e.g., 
employment, self-care, social interaction, etc.
44,45
 
Opposite to the aforementioned findings, in a study 
by Dahl et al. there was no association between the 
prevalence of depression and level of disability in MS 
patients.
12
 In their study, there was no difference in 
disease duration between depressed and non-
depressed MS patients,
12
 whereas Seyed Saadat et al. 
and Montel et al.
11,13
 reported on older age and SPMS 
course as risk factors for developing depression. 
These diverse findings in the studies assessing the 
link between the presence of depression and disease-
related or epidemiological parameters may be 
explained by different study designs (e.g., patient 
selection from administrative databases or community 
sample, usage of diagnostic questionnaires or formal 
diagnostic interviews), different sample size, and 
regional and cultural differences.
11-14
 Unlike the 
aforementioned studies, in our study respondents 
were MS patients referred for inpatient rehabilitation, 
which could also have an impact on the results. The 
latter means that the analysis excluded some of those 
with short disease duration associated with low 
functional deficit, younger age, and relapsing-
remitting course because these patients are rarely 
treated as inpatients. 
Despite these limitations, the results of our study 
indicated the prevalence of depression to increase 
with the increasing degree of disability irrespective of 




In the present study, the prevalence of depression 
based on the PHQ-9 questionnaire in patients with 
MS was 30.4%. Considering the high prevalence of 
depression on the screening test and the fact that only 
one-third of depression  positive patients were taking 
antidepressants, there is a need to actively look for 
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